Stripping cells from donor tissue leaves a natural scaffold ready for a patient's own cells
Every organ or tissue harvested for transplant arrives packed with its original resident cells, each nucleus carrying donor MHC antigens the recipient's immune system will recognize as foreign. Decellularization exists to remove that liability while keeping everything else.
Transplant rejection is driven almost entirely by cellular and nuclear material — surface MHC/HLA proteins and residual donor DNA are what a recipient's immune system detects and attacks. The structural extracellular matrix itself (collagen, laminin, elastin) is largely conserved across individuals and is comparatively non-immunogenic.
Whole organs already contain a branching network of vessels down to the capillary level, built by developmental biology to deliver nutrients to every cell. That same plumbing becomes the delivery route for decellularization reagents — and later, for reseeding — making whole-organ perfusion far more efficient than soaking tissue in a bath.
Cadaveric or discarded organs unsuitable for direct transplant (due to size, age, or minor damage) are common sources, since decellularization does not require living, functioning tissue — only intact ECM architecture and a patent vascular tree.
Ott et al. (2008, Nature Medicine) first demonstrated whole-organ decellularization and recellularization of a rat heart via coronary perfusion — the founding proof of concept for this entire field.
Detergents, enzymes, and physical disruption are delivered through the vascular network at controlled pressure, lysing cells in place and flushing the debris out the same channels — leaving the surrounding matrix largely undisturbed.
Stronger detergents and longer perfusion times clear cells and DNA more completely, but at the cost of stripping glycosaminoglycans, damaging collagen crosslinks, and reducing growth-factor retention. Every protocol is a trade-off tuned to the specific tissue's density and vascular fragility.
Most practical protocols combine methods sequentially — a detergent wash to lyse cells, followed by enzymatic digestion to clear nucleic acids, sometimes bracketed by freeze-thaw cycles — rather than relying on any single reagent.
Perfusion pressure and effluent turbidity are tracked continuously; a clearing, straw-colored effluent and falling perfusion resistance signal that cellular material is being successfully evacuated from the vascular bed.
Over-perfusion is a real risk: excessive detergent exposure or duration measurably degrades collagen fiber diameter and reduces the mechanical strength of the finished scaffold.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| SDS Perfusion | Cell membranes, cytoplasm | Ionic detergent solubilizes lipid bilayers and denatures proteins | Most effective at complete decellularization |
| Triton X-100 | Cell membranes | Non-ionic detergent disrupts lipid-lipid & lipid-protein bonds, gentler on matrix | Better preserves glycosaminoglycans |
| Enzymatic (Trypsin, DNase/RNase) | Cell adhesion proteins, nucleic acids | Proteolytic cleavage of anchoring proteins; nucleases degrade residual DNA/RNA | Precisely targets residual nucleic acids |
| Freeze–Thaw | Whole cells | Ice crystal formation ruptures cell membranes physically | No chemical residue, low cytotoxicity risk |
The finished scaffold is optically translucent, entirely free of nuclear material, yet retains the native three-dimensional fiber architecture and the full branching vascular network — a biological template ready to be repopulated.
Crapo et al. (2011) established the field's benchmark: fewer than 50 ng of double-stranded DNA per mg of dry ECM weight, no visible nuclear material by DAPI or H&E staining, and any residual DNA fragments shorter than 200 base pairs — too short to trigger a meaningful immune response.
What makes the scaffold valuable is not its chemical composition alone but its native three-dimensional microarchitecture: collagen fiber orientation, basement membrane composition, and pore geometry that synthetic scaffolds struggle to replicate, all of which guide how new cells attach, migrate, and differentiate.
Because the vascular channels were never destroyed — only emptied — the scaffold retains a complete, anatomically correct conduit system down to small vessels, an infrastructure advantage no synthetic or 3D-printed scaffold can fully match yet.
Retained signaling molecules like VEGF and basic fibroblast growth factor (bFGF), physically trapped within the ECM during decellularization, measurably improve seeded-cell attachment and differentiation versus synthetic polymer scaffolds.
Autologous or patient-derived cells are introduced through the preserved vasculature, using the same perfusion infrastructure that once carried decellularization reagents — now delivering living cells to their native anchoring sites.
Just as decellularization used the vasculature to reach every corner of the organ, recellularization uses it again — perfusing cell suspensions through the same channels ensures new cells are delivered deep into the tissue, not just seeded on exposed surfaces.
Lining the vascular channels with endothelial cells first is critical: an exposed, bare ECM surface inside a vessel is thrombogenic and will trigger clotting the moment blood flow is restored, so vascular re-endothelialization is typically attempted before parenchymal cell types are introduced.
Different regions of the scaffold require different cell types delivered by different routes — vascular endothelial cells via the vessel lumen, parenchymal cells (cardiomyocytes, hepatocytes, etc.) via interstitial or airway/ductal routes depending on the organ.
Native ECM composition actively directs differentiation: stem and progenitor cells seeded onto organ-specific decellularized matrix tend to adopt phenotypes matching that organ more readily than on generic synthetic scaffolds.
A fully repopulated scaffold combines the patient's own living cells with a native-derived structural matrix, aiming for a graft the immune system does not recognize as foreign. The approach works at small scale; whole complex organs remain a frontier.
Small, thin, or simple tissues — heart valves, tracheal segments, dermal and vascular grafts, and some bladder tissue — have reached or approached clinical use built on decellularized scaffolds, validating the core biological premise repeatedly since Doris Taylor's lab first published in 2008.
Complete, functional endothelialization of an organ's entire capillary bed — millions of vessels down to micron scale — to prevent clotting under physiological blood flow is the single largest unsolved engineering problem standing between bench-scale rat hearts and a transplantable human kidney, lung, or liver.
Even a scaffold that passes DNA-content criteria can retain cytotoxic traces of detergent if rinsing is incomplete, so thorough post-decellularization washout and residual-reagent testing remain essential quality-control steps before any recellularization attempt.
The long-term goal is a patient-specific, off-the-shelf-adjacent organ pipeline: decellularize a donor or even xenogeneic scaffold, then recellularize it with the recipient's own cells — sidestepping both donor shortage and lifelong immunosuppression.